We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Revises Guidance for Its “PRIME Scheme” Drug Development Assistance Program
EMA Revises Guidance for Its “PRIME Scheme” Drug Development Assistance Program
EMA has issued revised guidance for its PRIority MEdicines (PRIME) scheme that provides early consultation and scientific advice between applicants and regulators for medicines under development and not currently authorized in the EU.